Amgen lifts 2026 profit, revenue forecasts; shares down

** Shares of drugmaker Amgen AMGN.O fall 2.2% to $455.60 in extended trading

** Quarterly sales of osteoporosis drug Prolia fell 45% to $632 million, missing analysts' estimates of $697 million - LSEG data

** Sales of thyroid eye disease drug Tepezza sales fell 6% to $526 million in Q3 below estimates of $569.5 million

** Q3 sales of rare disease drug Tavneos also fell 2% to $105 million

** Co raises its 2026 annual adjusted profit forecast to $22.90 to $23.70 per share, compared with its prior outlook of $22.30 to $23.50 per share

** Lifts annual revenue forecast to a range of $38.9 billion to $39.7 billion, from $38.2 billion to $39.4 ​billion previously

** Posts Q3 total revenue of $10.4 billion above analysts' estimate ​of $10.1 billion

** Reports adjusted profit per share for the quarter $6.45 vs estimates of $5.79

** Guggenheim says stronger sales of Uplizna, Imdelltra and Enbrel drove the revenue beat, offset in part by weaker sales of Tepezza, Prolia

** As of last close, stock up 40.9% YTD